【what's my kibbe body type】Toll Brothers Makes Wedbush's Best Ideas List: Here's Why
Shares of luxury homebuilder
Toll Brothers Inc
(NYSE:
TOL
) are advancing Wednesday following an upbeat commentary on the company's prospects by an analyst at Wedbush.
Thewhat's my kibbe body type Toll Brothers Analyst
Jay McCanless
has an Outperform rating and a $48 price target for
Toll Brothers
. Wedbush also added the stock to its Best Ideas List.
The Toll Brothers Thesis
Order growth at Toll Brothers has surpassed expectations in the last two quarters, McCanless said in a Wednesday note. Given the easy prior year comps and sequential community growth through fiscal year 2020 ending October, the analyst sees double-digit percentage order growth as achievable for the remainder of the year.
The two price increases the homebuilder has already announced in 2020 and the likelihood of more increases should help profitability ramp from fiscal year 2020 to 2021, McCanless said.
The analyst expects 36% year-over-year EPS growth for 2021, as homes sold now will close starting in fiscal year 2021 and have 180 basis points higher gross margin than homes closed in 2020.
Share repurchase, according to the analyst, is another catalyst. The company signaled at its first quarter earnings call it would be an active buyer of its stock at current levels, McCanless noted.
Wedbush said valuation of shares are attractive, given they are trading at a discount to the homebuilder group, both on P/E basis and on the basis of Price/tangible book value.
TOLL Price Action
Toll Brothers shares were up 3.46% to $40.312.
Related Links
Analyst: Toll Brothers Holds 'Strong And Flexible Position,' Can Navigate Economic Challenges
Trade War Fears Trigger Nomura Instinet's Downgrade Of Housing Stocks
Photo by Tom Rumble on Unsplash
Latest Ratings for TOL
Feb 2020
Wedbush
Upgrades
Neutral
Outperform
Feb 2020
Raymond James
Downgrades
Outperform
Market Perform
Feb 2020
RBC Capital
Upgrades
Sector Perform
Sector Outperform
View More Analyst Ratings for TOL
View the Latest Analyst Ratings
See more from Benzinga
Nano-Cap Cellect Biotechnology Rips Higher On Medical Cannabis Deal
Tesla Blames COVID-19 Impact For Model 3 Hardware Botch In China, Promises Free Replacement
Vir Biotech, Alnylam Stitch COVID-19 Therapy Partnership
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
View comments
本文地址：http://anorchous.ooovvveuisey.bond/html/019a399977.html
版权声明
本文仅代表作者观点，不代表本站立场。
本文系作者授权发表，未经许可，不得转载。